Drug intelligence / Profile preview

mirdametinib + vorinostat

Development stage: Unknown
Lead developer: SpringWorks Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Mirdametinib + vorinostat is an investigational oral combination therapy being studied primarily for the treatment of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors (NF1-MPNST). Mirdametinib is a potent, CNS-penetrant allosteric small molecule inhibitor of MEK1 and MEK2 in the MAPK pathway, which regulates cell growth and survival. Vorinostat is a histone deacetylase inhibitor that modulates gene expression by altering chromatin structure. The combination aims to synergistically inhibit tumor growth by targeting both signaling pathways and epigenetic regulation[1][2][3].

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on mirdametinib + vorinostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mirdametinib + vorinostat.

Explore the full profile